全文获取类型
收费全文 | 2159468篇 |
免费 | 154162篇 |
国内免费 | 2838篇 |
专业分类
耳鼻咽喉 | 29505篇 |
儿科学 | 70367篇 |
妇产科学 | 59056篇 |
基础医学 | 314890篇 |
口腔科学 | 60368篇 |
临床医学 | 197347篇 |
内科学 | 414229篇 |
皮肤病学 | 47891篇 |
神经病学 | 169112篇 |
特种医学 | 82236篇 |
外国民族医学 | 461篇 |
外科学 | 315875篇 |
综合类 | 44631篇 |
现状与发展 | 3篇 |
一般理论 | 781篇 |
预防医学 | 167080篇 |
眼科学 | 49336篇 |
药学 | 165367篇 |
11篇 | |
中国医学 | 4524篇 |
肿瘤学 | 123398篇 |
出版年
2018年 | 22625篇 |
2017年 | 17512篇 |
2016年 | 19492篇 |
2015年 | 22158篇 |
2014年 | 30633篇 |
2013年 | 45945篇 |
2012年 | 62696篇 |
2011年 | 66575篇 |
2010年 | 38977篇 |
2009年 | 37135篇 |
2008年 | 62583篇 |
2007年 | 66951篇 |
2006年 | 67221篇 |
2005年 | 64973篇 |
2004年 | 62334篇 |
2003年 | 59916篇 |
2002年 | 57925篇 |
2001年 | 104434篇 |
2000年 | 106861篇 |
1999年 | 89677篇 |
1998年 | 23947篇 |
1997年 | 21466篇 |
1996年 | 21657篇 |
1995年 | 20350篇 |
1994年 | 18845篇 |
1993年 | 17700篇 |
1992年 | 69536篇 |
1991年 | 67585篇 |
1990年 | 66038篇 |
1989年 | 63846篇 |
1988年 | 58459篇 |
1987年 | 57045篇 |
1986年 | 54200篇 |
1985年 | 51062篇 |
1984年 | 38057篇 |
1983年 | 32748篇 |
1982年 | 18784篇 |
1981年 | 16726篇 |
1979年 | 35318篇 |
1978年 | 24969篇 |
1977年 | 21554篇 |
1976年 | 19450篇 |
1975年 | 21437篇 |
1974年 | 25623篇 |
1973年 | 25011篇 |
1972年 | 23820篇 |
1971年 | 22298篇 |
1970年 | 20826篇 |
1969年 | 19869篇 |
1968年 | 18170篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
22.
Janitz Amanda E. Schraw Jeremy M. Xu Chao Lupo Philip J. 《Cancer causes & control : CCC》2022,33(3):483-488
Cancer Causes & Control - Congenital malformations are strong risk factors for childhood cancer. Our objective was to determine whether cancer survival differs by birth defect status among... 相似文献
23.
Malunguja Gisandu K. Devi Ashalata 《Proceedings of the National Academy of Sciences, India. Section B.》2022,92(1):105-120
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - Heavy metal concentrations in surface soils of Reserved Forests (RFs) have a significant impact on... 相似文献
24.
Byrne Emma Abel Stephen Yu Alexander Shepard Matthew Karlovits Stephen M. Wegner Rodney E. 《Journal of neuro-oncology》2022,157(1):197-205
Journal of Neuro-Oncology - Adjuvant radiation is often used in patients with low grade gliomas with high-risk characteristics with a recommended dose of 45–54 Gy. We used the... 相似文献
25.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献
26.
27.
28.
Esin Benli Küçük Ercan Kaydok Kürsad Ramazan Zor Gamze Yıldırım Biçer 《Topics in stroke rehabilitation》2020,27(8):630-635
ABSTRACT Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group. Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared. Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group. Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients. 相似文献
29.
30.